Literature DB >> 10760520

Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis.

S A Keogh1, H Walczak, L Bouchier-Hayes, S J Martin.   

Abstract

Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines that promotes apoptosis and NF-kappaB activation. Here we show that recombinant hu-TRAIL initiates the activation of multiple caspases, the loss of mitochondrial transmembrane potential, the cleavage of BID and the redistribution of mitochondrial cytochrome c. However, whereas Bcl-2 efficiently blocked UV radiation-induced cytochrome c release and consequent apoptosis of CEM cells, it failed to do either in the context of TRAIL treatment. Thus, TRAIL engages a death pathway that is at least partially routed via the mitochondria, but in contrast with other stimuli that engage this pathway, TRAIL-induced cytochrome c release is not regulated by Bcl-2.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10760520     DOI: 10.1016/s0014-5793(00)01375-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses.

Authors:  Y Shi; W Zheng; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

2.  Cytotoxic necrotizing factor 1 prevents apoptosis via the Akt/IkappaB kinase pathway: role of nuclear factor-kappaB and Bcl-2.

Authors:  Alessandro Giamboi Miraglia; Sara Travaglione; Stefania Meschini; Loredana Falzano; Paola Matarrese; Maria Giovanna Quaranta; Marina Viora; Carla Fiorentini; Alessia Fabbri
Journal:  Mol Biol Cell       Date:  2007-05-16       Impact factor: 4.138

3.  Vasopressin Impairment During Sepsis Is Associated with Hypothalamic Intrinsic Apoptotic Pathway and Microglial Activation.

Authors:  Luis Henrique Angenendt da Costa; Nilton Nascimento Dos Santos Júnior; Carlos Henrique Rocha Catalão; Tarek Sharshar; Fabrice Chrétien; Maria José Alves da Rocha
Journal:  Mol Neurobiol       Date:  2016-09-08       Impact factor: 5.590

4.  Induction of apoptosis in human Hep3B hepatoma cells by norcantharidin through a p53 independent pathway via TRAIL/DR5 signal transduction.

Authors:  Chung-Hsin Yeh; Yu-Yen Yang; Ya-Fang Huang; Kuan-Chih Chow; Ming-Feng Chen
Journal:  Chin J Integr Med       Date:  2012-08-31       Impact factor: 1.978

5.  Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo.

Authors:  Keli Song; Nordine Benhaga; Robin L Anderson; Roya Khosravi-Far
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

6.  Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner.

Authors:  Ingo H Engels; Gudrun Totzke; Ute Fischer; Klaus Schulze-Osthoff; Reiner U Jänicke
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

Review 7.  TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

Authors:  R K Srivastava
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

8.  Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation.

Authors:  Martin Leverkus; Martin R Sprick; Tina Wachter; Thilo Mengling; Bernd Baumann; Edgar Serfling; Eva-B Bröcker; Matthias Goebeler; Manfred Neumann; Henning Walczak
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

9.  Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8.

Authors:  Martin R Sprick; Eva Rieser; Heiko Stahl; Anne Grosse-Wilde; Markus A Weigand; Henning Walczak
Journal:  EMBO J       Date:  2002-09-02       Impact factor: 11.598

10.  Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2.

Authors:  I-K Kim; Y-K Jung; D-Y Noh; Y-S Song; C-H Choi; B-H Oh; E S Masuda; Y-K Jung
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.